Together, these results indicate that CDKN1A is under the control of SLFN11-NFκB2 signaling in GBM and raise the possibility that p21 mediates, at least in part, the antineoplastic effects observed after SLFN11 loss (see Fig. 2). Here, CDKN1A is linked to glioblastoma.